Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 5/20 | 0.32 |
| ▸ | LSS | P48449 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22162579 | 0.91 | HTR7 (0.32) | HTR7GAATRPA1POLB | |
| SCHEMBL20247888 | 0.87 | GAA (0.33) | HTR7GAATRPA1POLB | |
| SCHEMBL24486076 | 0.84 | FDPS (0.33) | — | |
| SCHEMBL26798425 | 0.83 | GNAI3 (0.31) | — | |
| SCHEMBL23733479 | 0.80 | GNAI3 (0.34) | BCHELSSPOLB | |
| SCHEMBL23733446 | 0.80 | GNAI3 (0.34) | BCHELSSPOLB | |
| SCHEMBL18885278 | 0.78 | MAPT (0.44) | BCHELSSPOLB | |
| SCHEMBL20323067 | 0.78 | MAPT (0.44) | BCHELSSPOLB | |
| SCHEMBL24087947 | 0.78 | MAPT (0.44) | BCHELSSPOLB | |
| SCHEMBL18885424 | 0.78 | MAPT (0.44) | BCHELSSPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | INCYTE CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | PIK3R5, PIK3CD, PIK3CA | HTR7 3523/4885BCHE 4630/4885LSS 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.